News & Updates
Myosin Therapeutics Receives FDA Fast Track Designation for MT-125 in Glioblastoma
Jupiter, FL, [October 22, 2025] — Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies that modulate molecular motor proteins, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to MT-125 for the treatm...
Read moreMyosin Therapeutics Publishes Two Foundational Studies in the Journal Cell Highlighting a Novel Approach to Treating Cancer and Brain Disorders
Jupiter, FL – Myosin Therapeutics, a clinical-stage biotechnology company advancing first-in-class therapies targeting molecular motor proteins, announced the publication of two major papers in the journal Cell that establish non-muscle myosin II (NMII) as a druggable target with broad therapeutic i...
Read moreMyosin Therapeutics Receives FDA Clearance to Initiate First-in-Human Trial of MT-125 in Glioblastoma
Jupiter, FL – Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies targeting molecular motors, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for MT-125. The activ...
Read moreMyosin Therapeutics Announces Key Additions to Its Team as It Prepares to Start Multiple Clinical Trials in Q1 2025
Jupiter, FL - [October 2nd, 2024] – Myosin Therapeutics is pleased to announce the addition of three highly accomplished professionals to its team, further strengthening the company’s expertise as it prepares for upcoming clinical trials. Dr. Alfredo Quinones-Hinojosa has joined as a Scientific Advi...
Read moreMyosin Therapeutics' Patent Portfolio Strengthened with New Issued Statuses in Australia, Japan, Canada, and Korea
Jupiter, FL - [September 12th, 2024] – Myosin Therapeutics is pleased to announce the expansion and strengthening of its patent portfolio for its lead compounds MT-110 and MT-125, with newly granted and issued status in the key jurisdictions of Australia, Japan, Canada, and Korea. These recent grant...
Read moreMyosin Therapeutics Announces Successful Completion of GMP Drug Substance Manufacturing Campaign for MT-125
Jupiter, FL - [August 31st, 2024] – Myosin Therapeutics is pleased to announce that it has successfully completed a Good Manufacturing Practice (GMP) drug substance manufacturing campaign, yielding several kilograms of GMP MT-125 material. This achievement marks a significant step forward in the pre...
Read moreToday, Myosin Therapeutics Announces FDA Orphan Drug Designation for MT-125 for the Treatment of Malignant Gliomas
Jupiter, FL - [February 21, 2024] – Today, Myosin Therapeutics is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for MT-125 for the treatment of malignant gliomas, including glioblastoma (GBM), the most common and lethal glioma. Despite...
Read moreMyosin Therapeutics Transitions MT-110 to GMP Manufacturing After Meeting Milestones in NIH Blueprint Neurotherapeutics Program
Jupiter, FL - [August 1st, 2023] – Myosin Therapeutics is pleased to announce the successful completion of key milestones in the National Institutes of Health (NIH) Blueprint Neurotherapeutics (BPN) Program for its lead compound, MT-110, which is undergoing preclinical testing as a novel therapeutic...
Read moreDr. Courtney Miller Honored with BioFlorida’s 2022 Weaver H. Gaines Entrepreneur of the Year Award
Jupiter, FL - [November 15, 2022] – Myosin Therapeutics is honored to announce that its Chief Executive Officer and Chair of the Board of Directors, Dr. Courtney Miller, received BioFlorida’s 2022 Weaver H. Gaines Entrepreneur of the Year award. This prestigious honor recognizes Dr. Miller’s signifi...
Read more